DIPSS Plus Score for Prognosis in Myelofibrosis
Estimate prognosis in myelofibrosis.
Questions
About
The DIPSS was proposed and validated by Passamonti et al to estimate prognosis in myelofibrosis.
The DIPSS plus score further refines the prior prognostic scoring system with the addition of DIPSS-independent risk factors, including karyotype, transfusion dependency and platelet count. The score was developed and validated by Gangat et al.
Prognosis based on 6 point scoring system:
- If score is 0: Patient is considered "low risk" according to the DIPSS plus system. Median survival is estimated to be 180 months
- If score is 1: Patient is considered "intermediate-1 risk" according to the DIPSS plus system. Median survival is estimated to be 80 months
- If score is 2-3: Patient is considered "intermediate-2 risk" according to the DIPSS plus system. Median survival is estimated to be 35 months
- If score is 4 or more: Patient is considered "high risk" according to the DIPSS plus system. Median survival is estimated to be 16 months
References
Gangat et al.
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011 February 1, 29 (4): 392-7
Passamonti et al.
Blood 2010 March 4, 115 (9): 1703-8
The DIPSS Plus Score for Prognosis in Myelofibrosis calculator is created by QxMD.
By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.